...
首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >Coadministration of a Liver X Receptor Agonist and a Peroxisome Proliferator Activator Receptor-alpha Agonist in Mice:Effects of Nuclear Receptor Interplay on High-Density Lipoprotein and Triglyceride Metabolism in Vivo
【24h】

Coadministration of a Liver X Receptor Agonist and a Peroxisome Proliferator Activator Receptor-alpha Agonist in Mice:Effects of Nuclear Receptor Interplay on High-Density Lipoprotein and Triglyceride Metabolism in Vivo

机译:肝X受体激动剂和过氧化物酶体增殖物激活因子受体-α激动剂在小鼠中的共同给药:核受体相互作用对体内高密度脂蛋白和甘油三酸酯代谢的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Liver X receptors (LXRs) are master transcription factors regulating cholesterol and fatty acid metabolism.Treatment of C57B6 mice with a specific synthetic LXR agonist,N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1(trifluoromethyl)-ethyl]phenyl]-benzenesulfonamide (T0901317),resulted in elevated high-density lipoprotein (HDL) cholesterol as well as plasma and liver triglycerides.Peroxisome proliferator-acti-vated receptor-a (PPARa) agonists are known to induce per-oxisomal fatty acid beta-oxidation and also mediate HDL cholesterol metabolism.We have explored the hypothesis that simultaneous activation of PPARa and LXR may lead to additive effects on HDL cholesterol elevation as well as attenuation of triglyceride accumulation.Coadministration of T0901317 and the specific PPARa agonist [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (Wy14643)] in mice led to synergistic elevation of HDL cholesterol that was primarily associated with enlarged HDL particles enriched with apoE and apoAI.Liver phospholipid transfer protein (PLTP) mRNA and plasma PLTP activity were additively elevated,suggesting a role of PLTP in the observed HDL cholesterol elevation.Moderate increases in plasma triglyceride levels induced by LXR activation was reduced,whereas the accumulation of triglyceride in the liver was not altered upon Coadministration of the PPARalpha agonist.Per-oxisomal fatty acid beta-oxidation in the liver was dramatically elevated upon PPARa activation as expected.Interestingly,activation of LXRs via T0901317 also led to a significant increase in peroxisomal fatty acid beta-oxidation.Sterol regulatory element binding protein 1c expression was dramatically up-regulated by the LXR agonist but was not changed with PPARa agonist treatment.Liver lipoprotein lipase expression was additively increased upon LXR agonist and PPARa agonist coad-ministration.Our studies mark the first exploration of nuclear receptor interplay on lipid homeostasis in vivo.
机译:肝X受体(LXRs)是调节胆固醇和脂肪酸代谢的主要转录因子。用特定的合成LXR激动剂N-(2,2,2-三氟乙基)-N- [4- [2,2, 2-三氟-1-羟基-1(三氟甲基)-乙基]苯基]-苯磺酰胺(T0901317),导致高密度脂蛋白(HDL)胆固醇以及血浆和肝甘油三酸酯升高。过氧化物酶体增殖物激活的受体已知a(PPARa)激动剂可诱导过氧化物酶体脂肪酸β-氧化并介导HDL胆固醇代谢。我们探索了以下假设,即PPARa和LXR的同时激活可能导致对HDL胆固醇升高的附加作用以及对HDL的衰减作用。在小鼠中共同使用T0901317和特异性PPARa激动剂[4-氯-6-(2,3-二甲苯基)-2-嘧啶基硫代乙酸(Wy14643)]可导致HDL胆固醇的协同升高,这主要与HDL升高有关颗粒富集w肝脏磷脂转移蛋白(PLTP)mRNA和血浆PLTP活性相加增加,提示PLTP在观察到的HDL胆固醇升高中的作用.LXR激活诱导的血浆甘油三酸酯水平适度增加,而并用PPARalpha激动剂不会改变肝脏中的甘油三酸酯.PPARa激活后,肝脏中的过氧异麦芽酮酸β-氧化显着升高。有趣的是,通过T0901317激活LXRs也导致过氧化物酶体脂类的显着增加LXR激动剂显着上调了甾醇调节元件结合蛋白1c的表达,但PPARa激动剂处理并没有改变它的表达.LXR激动剂和PPARa激动剂的共沉淀使肝脏脂蛋白脂肪酶的表达增加。首次探索核受体在体内脂质稳态中的相互作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号